The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Evangelos Terpos

University of Athens School of Medicine

Alexandra General Hospital

Department of Clinical Therapeutics

80 Vas. Sofias Avenue

Greece

[email]@imperial.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of Athens School of Medicine, Alexandra General Hospital, Department of Clinical Therapeutics, 80 Vas. Sofias Avenue, Greece. 2012
  • General Air Force Hospital, Department of Haematology & Medical Research, 3 Kanellopoulou Street, GR-11525, Greece. 2008
  • Department of Hematology and Medical Research, 251 General Air Force Hospital, Athens, Greece. 2005 - 2008
  • Department of Hematology, Faculty of Medicine Imperial College, Hammersmith Hospital, Du Cane Road, United Kingdom. 2003 - 2006

References

  1. Sclerostin: a possible target for the management of cancer-induced bone disease. Gkotzamanidou, M., Dimopoulos, M.A., Kastritis, E., Christoulas, D., Moulopoulos, L.A., Terpos, E. Expert Opin. Ther. Targets (2012) [Pubmed]
  2. Bortezomib in multiple myeloma. Terpos, E., Roussou, M., Dimopoulos, M.A. Expert. Opin. Drug. Metab. Toxicol (2008) [Pubmed]
  3. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Terpos, E., Dimopoulos, M.A., Sezer, O. Leukemia (2007) [Pubmed]
  4. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia. Terpos, E., Anagnostopoulos, A., Kastritis, E., Bamias, A., Tsionos, K., Dimopoulos, M.A. Br. J. Haematol. (2006) [Pubmed]
  5. Biochemical markers of bone metabolism in multiple myeloma. Terpos, E. Cancer Treat. Rev. (2006) [Pubmed]
  6. What's new in bone research--anabolics, tissue repair, therapeutic strategies and more. Terpos, E. IDrugs (2006) [Pubmed]
  7. The role of markers of bone remodeling in multiple myeloma. Terpos, E., Politou, M., Rahemtulla, A. Blood Rev. (2005) [Pubmed]
  8. Myeloma bone disease: pathophysiology and management. Terpos, E., Dimopoulos, M.A. Ann. Oncol. (2005) [Pubmed]
  9. Current treatment options for myeloma. Terpos, E., Rahemtulla, A., Dimopoulos, M.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  10. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Terpos, E., Mihou, D., Szydlo, R., Tsimirika, K., Karkantaris, C., Politou, M., Voskaridou, E., Rahemtulla, A., Dimopoulos, M.A., Zervas, K. Leukemia (2005) [Pubmed]
  11. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Terpos, E., Politou, M., Viniou, N., Rahemtulla, A. Leuk. Lymphoma (2005) [Pubmed]
  12. Bisphosphonate treatment for multiple myeloma. Terpos, E., Rahemtulla, A. Drugs. Today (2004) [Pubmed]
  13. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J.M., Rahemtulla, A. Blood (2003) [Pubmed]
 
WikiGenes - Universities